Oral Oncology
Volume 46, Issue 1 , Page e1 , January 2010

Osteonecrosis of the jaws induced by drugs other than bisphosphonates – A call to update terminology in light of new data

Received 5 October 2009 ,Accepted 6 October 2009.

References 

  1. Marx RE, Sawatari Y, Fortin M. Broumand V Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567–1575
  2. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol. 2008;19:2091–2092
  3. Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest. 2009;27:221–226
  4. Stopeck A, Body JJ, Fujiwara Y, Lipton A, Steger GG, Viniegra M, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Europe J Cancer Suppl 2009;7:2 [abstract 2LBA].

PII: S1368-8375(09)00936-1

doi: 10.1016/j.oraloncology.2009.10.004

Oral Oncology
Volume 46, Issue 1 , Page e1 , January 2010

Article Tools